Renal cell carcinoma, VHL-associated

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 13:02, 6 June 2023 by Warner-admin (talk | contribs) (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1")
Jump to navigation Jump to search

Back to Top

Section editor transclusions Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.

1 regimens on this page
1 variants on this page


All lines of therapy

Belzutifan monotherapy

Regimen

Study Dates of enrollment Evidence
Jonasch et al. 2021 (MK-6482-004)
ESMO-MCBS (3)
2018-05-31 to 2019-03-29 Phase 2 (RT)

Targeted therapy

Continued indefinitely

References

  1. MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article PubMed https://clinicaltrials.gov/ct2/show/NCT03401788
Retrieved from "https://hemonc.org/w/index.php?title=Renal_cell_carcinoma,_VHL-associated&oldid=72338"